Skip to Content

Posts tagged with "Drug Development"

  • Drug Assays

    A New Antibiotic? Yes, Please

    New antibiotics against resistant Gram-negative bacteria make me happy, so I’m very glad to see this report from Genentech. They’ve been doing a lot of work on an antibiotic scaffold (arylomycins, Update: on a program that came in whey they bought RQx) which had not thus far really found much practical use, and it looks… Read More
  • Clinical Trials

    Digging Into the Genetics of Drug Targets

    Rare diseases – remember years ago, back when those were a case of market failure? When companies were reluctant to work on them because the market size was guaranteed to be small and you’d have to charge, like, a hundred thousand or more a year to make the whole idea financially viable? Which wasn’t going… Read More
  • Business and Markets

    Anarchist Drugs For All. Yeahboy.

    I’ve had numerous requests for my opinion about this article, so here it comes: it’s largely bullshit. It’s about “a volunteer network of anarchists and hackers developing DIY medical technologies”, and I can see why Vice.com is running the article, because that drugs/anarchists/hackers combo is absolute catnip to thei… Read More
  • Drug Development

    On Jadedness

    It’s a Friday in midsummer, so I assume that a fair percentage of the readership is not even around! So I’m not going to do a huge detailed blog post (got one of those coming on Monday, actually). Today I just wanted to go on a bit about a problem that comes with experience in… Read More
  • Alzheimer's Disease

    The Case of Verge Genomics

    A number of people have passed along the recent press stories about Verge Genomics, a new company out of YCombinator that has just raised $32 million for neuroscience drug discovery. Now that, as literally anyone who’s ever done it can tell you, is a hard field of a hard field, and I wish Verge good… Read More
  • Analytical Chemistry

    The Entropic Term is Laughing At Us

    There are plenty of things to optimize in a med-chem project other than binding affinity. But if you don’t have at least some level of binding, you may not have a med-chem project. And while from the outside, you might think that understanding how and why compound A binds to a given target while compound… Read More
  • Cancer

    Why Not Target DNA? Well. . .

    There are all sorts of small-molecule drugs that bind to protein targets. Active sites of enzymes are, of course, a big subset of those, but there are plenty of enzymes whose allosteric sites are known to host synthetic ligands as well. Membrane receptor and ion channel proteins get both of those mechanisms too, and then… Read More
  • Drug Development

    AI Will Not Threaten Pharma Patents – Not This Way

    I’d class this letter to Nature as “interesting but wrong”. Here’s the argument: . . .A patent is granted only when a compound’s application can be classified as both ‘new’ and ‘invented’. A highly effective compound thrown up by an AI algorithm could indeed be new. Whether it is ‘invented’, however, is debatab… Read More
  • Analytical Chemistry

    Looking Way Down Into the Cells

    Pharmacokinetics – the study of how drugs are taken up, distributed, metabolized, and cleared – is obviously a key part of drug development. Every drug substance gets handled somewhat differently by the human body, and these differences can completely determine whether you’ve got an effective therapy or not. But the tools we have… Read More
  • Clinical Trials

    Gene Therapy for Duchenne

    I have said unkind things about Sarepta’s drug for Duchenne muscular dystrophy, Exondys (eteplirsen). That’s because I did not think that there was enough information to approve it at the FDA, and I had trouble believing that its biochemical effects were enough to be meaningful in general. I have no reason to modify those opinions… Read More
123...